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Nuclear cardiology procedures are among the most extensively 
performed radionuclide studies. Procedures for the assessment 
of myocardial perfusion, contractile function and metabolism 
have gained a prominent position in clinical practice. Health 
risk to patients from radiopharmaceuticals results only from 
exposure to ionizing radiation. Nuclear medicine diagnostic pro-
cedures, including the cardiological ones, are accompanied by 
a very small risk of radiation induced malignant tumours. Death 
risk from stress and rest perfusion of myocardium (effective dose 
of about10 mSv) could be estimated as lower than 0.1 per mille.
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Introduction
In Poland — as in other European countries — nuclear 
cardiology procedures belong to most extensively performed 
scintigraphic studies. In the United States where nuclear cardio­
logy is particularly well developed, those procedures form more 
than 50% of all nuclear medicine procedures. A collective dose 
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from this source accounts for ~85 percent of the total dose to 
patients undergoing nuclear medicine diagnostics [1].
The contemporary nuclear medicine applies methods for the 
assessment of myocardial perfusion, contractile function, metabo­
lism, viability, innervation, and also detection of regions of necro­
sis and apoptosis in myocardium. Procedures for assessment of 
perfusion, contractile function and metabolism gained a prominent 
position in clinical practice. The most frequent procedure among 
those listed above is assessment of myocardial perfusion.
A gamma radiation is an information carrier in radionuclide 
diagnostics, the quanta of this radiation are emitted by short 
lived radionuclides introduced into the organism by means of 
injected radiopharmaceuticals. The role of a radiation emitter can 
be played by radioactive element or by a compound containing 
a radioactive atom in its structure. After intravenous injection 
radiopharmaceuticals are taken up, cumulated and eliminated 
from a myocardium or travel through heart cavities. Kinetics of 
these processes reflect various physiological functions and may 
reflect and localise abnormalities resulting from diseases of the 
heart and circulatory system. 
These processes can by registered by means of external 
measurements using scintillation cameras, thanks to high pe­
netration of gamma rays through patient body. The imaging instru­
ments enable both planar as well as tomographic visualization 
of myocardium by SPECT (single photon emission tomography) 
modality and by PET (positron emission tomography) techniques. 
(Additionally, X­rays produced by hybrid SPECT/CT and PET/CT 
instruments provide three­dimensional tissue density maps. Ba­
sing on transmission data it is possible to correct for the gamma 
ray absorption by tissues surrounding the heart. This procedure 
provides more accurate data on distribution of a radiopharmaceuti­
cal in myocardium [2]. Due to the fact that CT scanners mounted 
additionally on hybrid instruments work during cardiac studies in 
a low dose mode, use of CT rises a radiation to a patient only 
slightly (more precise values will be presented later).
The most important advances of nuclear cardiology are:
 — usually unique character of diagnostic information, normally 
very difficult to derive or just impossible to  obtain by other 
methods (like CT, MRI or ultrasonography). This applies to 
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regional  blood perfusion at the cardiomyocyte level and 
myocardial metabolism and provides a composite insight into 
blood perfusion and contractility of myocardium;
 — easy obtaining of required scintigraphic images. In contrast to 
echocardiography the anatomic conditions  only slightly affect 
quality and reliability of results;
 — semiquantitative or quantitative character of diagnostic in­
formations; 
 — good reproducibility of results. This is due to limitation of 
subjective factors in the process of their acquisition and pro­
cessing, usually semi­ or fully automatic;
 — noninvasiveness — radiopharmaceuticals are supplied to 
patients by intravenous injections. The mass administered 
is extremely small (usually in the order of micrograms in a few 
mililiters of physiological saline), therefore it does not influence 
a patient body in a noticeable way.
Radiation doses, health risk 
A health risk to patients from radiopharmaceuticals results only 
from exposure to ionizing radiation — gamma rays and posi­
trons — when PET technique is used, which in effect of annihila­
tions with electrons also produce some gamma rays.
The radiation risk depends on doses absorbed by patient or­
gans. The absorbed dose of radiation has been defined as a ratio 
of energy deposited and a mass of an absorbing tissue. The unit of 
absorbed radiation is 1 Gray (Gy) which equals 1 Joule of energy 
per  1 kg of tissue. The magnitude of such a dose is usually clas­
sified as large when it exceeds 1 Gy; low doses are those below 
0,1 Gy (100 mGy) [3]. Intermediate doses are those between the 
two classes defined above.
An effective dose has been defined by the ICRP (International 
Committee on Radiological Protection) [4] for an assessment of 
a risk to whole human body. This kind of dose takes into account 
different sensitivity of organs to radiation as well as different rela­
tive biological effectiveness of various kinds of ionizing radiation. 
However, in case of nuclear medicine studies relative biological 
effectiveness of radiations used for diagnostic purposes (gamma 
and beta plus) is equal to one. Therefore the effective dose is a sum 
of the products of absorbed doses in organs and tissues and 
their sensitivity factors. Radiopharmaceuticals cause differenti­
ated exposition of organs due to inhomogeneous distribution of 
activity in a human body. Radiopharmaceuticals used in nuclear 
cardiology also show affinity for another tissues and organs, like 
brain, thyroid, skeletal muscles, liver. Moreover, they are trans­
ported with body fluids and are secreted in gastro­intestinal and 
urinary tracts (Figure 1). This is why calculation of an effective dose 
resulting from administration of a radiopharmaceutical must take 
into account its distribution and kinetics in the whole body. The 
unit of the effective dose is named sievert [Sv]. In practice, for the 
assessment of the risk to patients smaller dose units are used 
(milisievert — 0.001 Sv). Effective doses to humans from gamma 
and beta plus  radiations emitted by radiopharmaceuticals ap­
plied in diagnostic cardiac procedures and, for comparison, also 
doses from X ray studies in several radiological procedures applied 
in cardiology are presented in Tables 1 and 2. As was mentioned 
earlier, additional use of low dose CT during cardiac SPECT of PET 
studies rises a radiation to a patient only slightly, by 1–1.5 mSv 
[5, 6]. It can be seen that both imaging modalities (nuclear 
medicine and radiological) are sources of similar or slightly 
lower effective doses, excepting interventional procedures (like 
percutaneous coronary angioplasty) that can expose patients to 
substantially higher radiation risk.
Biological effects of ionizing radiation in a human organism 
can be divided into two categories: deterministic and stochastic 
[3, 4]. The main mechanism of the former is death of an essential 
fraction of cells in a tissue or an organ caused by irradiation of 
a part or a whole organism. This damage cannot be repaired 
completely and spontaneously. Such effects are observed only 
when doses exceed threshold values for the tissue in question. 
The thresholds vary between 0.2 and several grays for various tis­
sues and organs. Those effects are never seen after application 
of a proper activity of a radiopharmaceutical used for diagnostic 
purpose.
Stochastic effects are those which appear in irradiated popula­
tions with incidence proportional to the dose; they are also called 
probabilistic. Stochastic effects result from damage to somatic 
and reproductive cells. Those cells which survive irradiation can 
become carriers of mutations caused by damage to DNA. Ef­
fects of such a damage can lead to development of malignant 
neoplasms, and if the damage was located in reproductive 
cells — to hereditary effects (which can appear in next genera­
tions). There is a common opinion (although contested by some 
investigators) that at low and intermediate doses the probability 
of induction of malignant tumors and hereditary effects is pro­
portional to the dose of radiation, without threshold. The risk of 
hereditary effects from ionizing radiation was so far evaluated only 
from studies on animals of different species. The direct data for 
humans exposed to low doses are not available at present. The 
ICRP evaluated the respective probability of the hereditary risk 
as being very low, 0.2% per Gy (or 2 × 10–6 per mGy) up to the 
second generation [7]. This is less than one tenth of the risk of 
fatal carcinogenesis following irradiation [7].
The mortality risk from malignant neoplasms, induced by io­
nizing radiation from diagnostic procedures in nuclear medicine 
has been estimated from extrapolations of the effect of doses in 
the order of 0,5–1,0 Sv, observed in several epidemiological stu­
 A  B
Figure 1. Biodistribution of radiopharmaceuticals. A. 99mTc-MIBI 
(myocardial perfusion study — SPECT); B. 18F-fluorodeoxyglucose 
(myocardial viability study — PET); a — heart; b — thyroid; c — liver; 
d — intestines; e — urinary bladder; f —kidneys; g — brain
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dies. So called nominal probability coefficient for fatal cancer 
published by ICRP equals 4% per Sievert [7]. A widely accepted 
linear non­threshold model of incidence of malignant tumours in 
relation to radiation dose leads to values about 1:400 000 per mSv. 
This means that death risk from fatal cancer caused by patient 
irradiation during stress and rest perfusion study of myocardium 
(effective dose 10 mSv) could be estimated as lower than of 0.1 
per mille. For better understanding of this risk: if a large population 
of people was exposed to analogous radiation dose, malignant 
neoplasms leading to death could be additionally expected in 
less than 0.1 pro mille of this population. One should remember 
that normal mortality from spontaneous malignant tumours in hu­
man populations amounts to 20–25% [3, 12].
In addition, one should also remember that potential effect 
of the discussed nature is delayed after irradiation. The shortest 
delay time of radiation induced leukemia equals 2–3 years (the 
average delay is 7 years) and for malignant solid tumours the 
analogous time intervals are 10–15 years (mean 20 y) [3]. 
In addition, the risk declines with age. The probability of cancer 
induction after exposure at the age of 60 years is 5 times lower 
than that after exposure at 20–40 years [3].
The sensitivity to radiation in utero life and the first decade 
after birth is 2–3 times higher than that given above for the whole 
population [3].
A nuclear medicine study, if conducted in a proper way 
and undertaken due to reasonable indications, carries potential 
health gains for a patient, exceeding by orders of magnitude the 
negative effects for health and life. In other words, refraining from 
a well motivated nuclear medicine procedure can be a source of 
incomparably higher risk to a patient.
Conclusion
Nuclear medicine  diagnostic procedures, including the car­
diological ones, are accompanied by a very small radiation risk. 
Nevertheless, patient exposure to ionizing radiation should observe 
following conditions [4]:
1. Proper justification of a well selected nuclear medicine pro­
cedure; 
2. Optimization of patient protection, i.e. exposure to possibly 
low doses but providing appropriate procedure and radio­
pharmaceutical activity to obtain useful result;
3. Avoiding nuclear medicine procedures in pregnant women 
(due to higher sensitivity of the embryo and fetus to ionizing 
radiation), especially that in many clinical situations there 
is a possibility to apply in women at that age other diagnostic 
studies that do not expose patients to ionizing radiation (like 
e.g. echocardiography).
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*Range of doses taken from literature published before 2007. Introduction of a new 
generation equipment and modern techniques of examination reduced the effective 
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